Therapeutic HIV vaccine

A therapeutic HIV vaccine is a vaccine that when used provides immunity to HIV and the resultant AIDS condition.

An effective HIV vaccine has been sought in medical research since the mid-1980s, although progress has been made only relatively recently. There is a small number of independent research groups working on potential HIV/AIDS vaccines.

One research group recently indicated that, whilst their vaccine did not prevent the disease, it could mitigate or halt the development of AIDS from HIV.

There are many therapeutic hiv/aids vaccine in development in all the world. Geovax vaccine Emory University USA is one of the best promising. Merck MRKAD5 is well advanced in phase IIb, but in September 2007, field tests were suspended due to doubts about whether the previous encouraging results were not the result of erroneous interpretation of previous test results.

According to the top U.S. infectious disease scientist Tony Fauci:

AIDS may be cured in a select group of patients who now have extremely low levels of virus in their bodies by aggressively dosing them for a year with new HIV drugs from Roche Holding AG and Merck & Co., according to the top U.S. infectious disease scientist.